Should you buy Harvard Bioscience stock now?
Yes, the technical signal for Harvard Bioscience is currently BUY. Harvard Bioscience trades at $6.26 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.040 with rising momentum (signal: 0.010); RSI is at 58.2 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $6.00 is 4.1% below the current price. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Harvard Bioscience stock?
The average analyst price target for Harvard Bioscience is $6.00. The current price is $6.26, which gives a downside of 4.1%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $5.40 and $6.60.
Is Harvard Bioscience a dividend stock?
No, Harvard Bioscience does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Harvard Bioscience stock?
Harvard Bioscience is rated as a stock with extreme risk. the annual standard deviation is 90.3%, which classifies the stock as extreme risk.
Is Harvard Bioscience overvalued?
Harvard Bioscience is considered fairly valued – the price is close to the analyst price target. Harvard Bioscience has the following valuation ratios: a P/S ratio of 0.3, a P/B ratio of 2.9. The stock trades close to the analyst price target and is considered fairly valued.
Is Harvard Bioscience overbought?
No, Harvard Bioscience is not overbought. RSI is at 58.2 (neutral zone). The technical indicators show: RSI is at 58.2 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 2.3% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Harvard Bioscience earnings report?
Harvard Bioscience reports its next earnings on August 11, 2026. The stock currently trades at $6.26.
Is Harvard Bioscience shorted?
Yes, Harvard Bioscience is shorted with 1.3% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Harvard Bioscience stock?
No, insiders are not buying Harvard Bioscience shares – they are net sellers. Across the last 20 reported transactions, the split is 13 purchases and 7 sales, with a net 204,879 $ sold. Active sellers include Green James W, Cote Jennifer. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Harvard Bioscience a good stock?
Based on our total score, Harvard Bioscience is rated as a poor stock with a total score of 35 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 41/100, Quality: 26/100, Momentum: 38/100. In addition: technical signal: Strong Buy. Whether Harvard Bioscience is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Harvard Bioscience stock?
The outlook for Harvard Bioscience based on current data: the average analyst price target is $6.00 (-4.1%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 8/11/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Harvard Bioscience stock rising?
Harvard Bioscience is rising right now. The technical indicators show: the price is 2.3% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Harvard Bioscience go?
The average analyst price target for Harvard Bioscience is $6.00, which is 4.1% below the current price of $6.26. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Harvard Bioscience fall?
We lack enough history to give a specific floor for Harvard Bioscience. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Harvard Bioscience do?
Harvard Bioscience, eller hbio.us, laver og sælger teknologi til forskning i biovidenskab, både i USA og internationalt. De tjener primært penge på at levere udstyr til laboratorier, som arbejder med celle- og molekyleanalyse.
Blandt deres produkter finder man avancerede infu... The company belongs to the Sundhed sector, more specifically the Medicinsk udstyr industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Harvard Bioscience as an investment.
Did Harvard Bioscience raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Harvard Bioscience. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Harvard Bioscience making money or losing money?
No, Harvard Bioscience is currently not making money — the company is losing money with a negative profit margin of -11.4%, a noticeable loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Harvard Bioscience go bankrupt?
The bankruptcy risk of Harvard Bioscience is rated as elevated. Altman Z2 (a model for assessing financial distress) is -7.63 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 5 — which is average. Debt relative to equity is 100% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Harvard Bioscience have a lot of debt?
Harvard Bioscience has moderate debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 100%. For the sundhed sector, 80-150% counts as a typical level. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Harvard Bioscience service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is -2.9x, and net debt equals 4.7 years of earnings (EBITDA).
